Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038766 · ClinicalTrials.gov registry record · Phase 2
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00038766 is a Phase 2 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT00038766, a Phase 2 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.
Interventions
- DRUG placebo
- DRUG semapimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038766
The ClinicalTrials.gov registry entry for NCT00038766 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00038766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038766 about?
NCT00038766 is a clinical study titled "CNI-1493 for Treatment of Moderate to Severe Crohn's Disease". The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.
What is the current status of trial NCT00038766?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2002-06. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00038766?
The interventions under investigation include: placebo (DRUG), semapimod (DRUG).
Who is sponsoring clinical trial NCT00038766?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.